ArticleGynecologic oncology2025
Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveLow-grade serous ovarian carcinoma (LGSOC) and high-grade serous ovarian carcinoma (HGSOC) are distinct entities. Although typically occurring in pure forms, some present as synchronous or metachronous mixed histotypes.
methodsThis retrospective study examined patients with mixed LGSOC and HGSOC treated between 1994 and 2024 at MD Anderson Cancer Center (MDACC). Diagnoses were confirmed by MDACC gynecologic pathologists. Demographics, clinical characteristics, diagnosis rendered by referral institution, treatment, immunohistochemistry, somatic tumor testing, and survival outcomes were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, with log-rank tests to compare cohorts, p < 0.05 significant.
resultsAmong 39 cases, 85 % were synchronous, and 15 % were metachronous. Seven (25 %) of patients tested for germline mutations (n = 28) had germline BRCA mutations. Of the 35 cases diagnosed at referral institutions, only eight (23 %) were correctly identified as mixed. Sixteen (41 %) patients underwent somatic tumor testing, revealing three KRAS, one NRAS, and eight TP53 mutations. All patients underwent cytoreductive surgery, with 97 % receiving adjuvant therapy and 26 % maintenance therapy. Recurrence occurred in 90 % of cases. Median PFS was 17 months, and median OS was 56.7 months, with a 5-year survival rate of 48.5 %. There was no statistically significant difference when comparing PFS or OS by BRCA status, primary vs interval cytoreduction, residual disease, tumor presentation, or maintenance therapy.
conclusionDiagnosing mixed LGSOC and HGSOC remains challenging. Despite low TP53 mutation rates, survival outcomes resembled those of HGSOC. These findings advocate for further investigations to identify risk factors and biomarkers for low-grade to high-grade transformation and to improve treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.